2A and 2B). We next examined the interactions between
We next tested a panel of kinases for their ability to Bub1 and other checkpoint proteins. Bub1 interacted phosphorylate Cdc20. Human polo-like kinase (Plk1), with Bub3 in HeLa cells throughout the cell cycle ( Figure  Mps1 , Aurora A, Aurora B, BubR1, p38MAPK, and ERK1 2C). Further fractionation of the cell lysates demonfailed to phosphorylate Cdc20 to a significant extent strated that the majority of Bub1 was bound with Bub3 ( Figure 2F ). These kinases efficiently phosphorylated ar-(data not shown). We did not observe significant interactificial substrates, such as MBP or casein ( Figure 2F ). tions between Bub1 and other checkpoint proteins (data Thus, phosphorylation of Cdc20 by Bub1 appears to be not shown). two members of the MAPK family, p38 and ERK1, failed Bub1-Bub3, consistent with the notion that Cdc20, not APC/C itself, is the target of Bub1 in the in vitro ubiquitito phosphorylate human Cdc20 in our in vitro kinase assays. We do not know the reason for this discrepancy. nation assays (data not shown). Finally, Bub1-Bub3 did not substantially inhibit APC/C Cdh1 ( Figure 3C ). Taken This might reflect a difference between the human and Xenopus Cdc20 proteins. Alternatively, MAPK might intogether, these data indicate that Bub1-Bub3 inhibits APC/C Cdc20 catalytically by phosphorylating Cdc20. directly regulate Cdc20 phosphorylation in Xenopus extracts.
Phosphorylation of Cdc20 by Bub1 required the intact Bub1 protein. Though capable of autophosphorylation, a C-terminal fragment of Bub1 (Bub1C) containing its Bub1 Inhibits APC/C Cdc20 Catalytically In Vitro We then tested the effects of Cdc20 phosphorylation kinase domain failed to phosphorylate Cdc20 ( Figure  3E ). Consequently, Bub1C failed to inhibit APC/C Cdc20 by Bub1 on the activity of APC/C Cdc20 in a reconstituted APC/C ubiquitination assay using a fragment of human ( Figure 3F Bub1 playing a role in phosphorylating Cdc20 in vivo, the slower migrating and phosphorylated forms of We purified the endogenous Cdc20 protein from noco- Figure 5C ). Phosphatase treatment reversed this mobility shift of nated most of Bub1-mediated phosphorylation of Cdc20. Importantly, Cdc20 BPM was as efficient as the wild-type Bub1, suggesting that Bub1 was hyperphosphorylated in checkpoint-active cells ( Figure 5C ). Furthermore, the Cdc20 protein (Cdc20 WT ) in promoting the ubiquitin ligase activity of APC/C, and Bub1-Bub3 failed to inhibit Bub1-Bub3 complexes isolated from nocodazole-or Taxol-arrested (metaphase) cells exhibited much higher the activity of the APC/C-Cdc20 BPM complex ( Figure 5B ). These results indicate that phosphorylation of Cdc20 by kinase activity toward Cdc20 as compared to Bub1 immunoprecipitated from the thymidine-arrested (G1/S) Bub1, rather than phosphorylation of other core APC/C subunits, is required for the inhibition of APC/C Cdc20 by cells ( Figure 5D ). The endogenous Bub1-Bub3 complex also phosphorylated Cdc20 at the same six sites deBub1. However, it cannot be ruled out that phosphorylation of APC/C itself by Bub1 also contributes to scribed above, since Cdc20 BPM was not significantly phosphorylated by the Bub1 immunoprecipitates (IP) APC/C inhibition. is hyperphosphorylated and its kinase activity toward Cdc20 is stimulated. However, we cannot rule out the possibility that the Bub1 IPs contain substoichiometric amounts of other kinases. 
Expression of the Nonphosphorylatable

Cdc20 BPM cells led to the accumulation of securin (Figure 6D). Induced expression of Myc-Cdc20
WT did not alter the protein levels of securin. In contrast, the securin level ( Figure 5D ). In addition, we performed a large-scale immunoprecipitation of the endogenous Bub1 complex. 
